Myeloma, Multiple Clinical Trial
Official title:
A Phase I, Open-Label, Multi-Center Study of CKD-581 in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
This study is to determine the maximum tolerated dose(MTD), dose limiting toxicity(DLT), safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination with Bortezomib and Dexamethasone in patients with Previously Treated Multiple Myeloma.
This is an open label, dose escalation study. Cohort of 3~6 patients receive escalation doses of CKD-581 until the maximum toleated dose(MTD) is determined. The MTD is defiend as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04009109 -
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
|
Phase 2 | |
| Terminated |
NCT03910439 -
Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT03150316 -
CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT03966443 -
Fluciclovine PET/CT in Multiple Myeloma Patients
|
||
| Completed |
NCT02294487 -
Study of the Immune Response After Vaccination in Multiple Myeloma Patients
|
||
| Recruiting |
NCT04645199 -
National Longitudinal Cohort of Hematological Diseases
|
||
| Completed |
NCT02033928 -
Comprehensive Frailty Assessment
|
N/A |